eligibility_summary
Adults (≥18) with relapsed/refractory multiple myeloma: either ≥2 prior therapies incl. lenalidomide and a proteasome inhibitor, planned elotuzumab + pomalidomide + dexamethasone, or 1–3 prior therapies, planned elotuzumab + lenalidomide + dexamethasone. Exclude: indications not approved in Taiwan, contraindications per Taiwan label, or participation in another interventional trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational post‑marketing safety study in Taiwan of two regimens for relapsed/refractory multiple myeloma: elotuzumab + pomalidomide + dexamethasone, and elotuzumab + lenalidomide + dexamethasone. Drug types and mechanisms: Elotuzumab is a humanized IgG1 monoclonal antibody against SLAMF7/CS1, it activates NK cells via SLAMF7 and engages Fcγ receptors to mediate ADCC against SLAMF7+ myeloma cells. Pomalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that bind cereblon, induce IKZF1/IKZF3 degradation, downregulate IRF4/MYC, enhance IL‑2 and T/NK‑cell activity, and have anti‑angiogenic/tumoricidal effects. Dexamethasone is a glucocorticoid that induces lymphoid apoptosis and augments anti‑myeloma therapy. Targets/pathways: SLAMF7 on myeloma and NK cells, Fc‑mediated ADCC, CRBN–IKZF axis, glucocorticoid receptor signaling.